Targeted Antibody for Blood Cancer Raises $90M
The Oxford spinout's lead candidate could offer selective treatment for essential thrombocythaemia, with human dosing not expected until 2028.
Updated on Nov. 5, 2026 in Biotech
Alethio Therapeutics, a biotech that spun out of the University of Oxford, closed an oversubscribed $90 million series A round. The round was co-led by Sofinnova Partners and RA Capital, with Oxford Science Enterprises participating as a founding investor and Cancer Research Horizons and the University of Oxford also contributing. The company is research-stage: its lead candidate, ATX-011, has not yet entered human trials.
Why it matters
The raise funds the advance of ATX-011, a mutation-agnostic antibody for essential thrombocythaemia, a blood cancer where current treatments can damage healthy cells. The round signals investor appetite for targeted, rather than broadly cytotoxic, therapies in myeloproliferative neoplasms.
The company reports a $90 million series A close, but no efficacy or safety figures for ATX-011 were disclosed. The only quantified claim is the round size, and the candidate's mechanism remains unvalidated in humans.
The players
Alethio Therapeutics
A biotech spun out of the University of Oxford that develops targeted therapies for myeloproliferative neoplasms using its ARTEMIS discovery engine.
Sofinnova Partners
A European life-sciences venture investor that co-led Alethio's series A round.
RA Capital
A life-sciences investment firm that co-led Alethio's series A round.
Oxford Science Enterprises
A University of Oxford-linked investor that participated as a founding investor in Alethio.
The details
ATX-011 is designed to normalise platelet counts by enhancing platelet clearance through binding to G6B, a receptor on platelets. Alethio builds its candidates with its ARTEMIS target-discovery and development engine, which it uses to identify and develop targeted therapies that selectively eliminate the cells driving myeloproliferative neoplasms (MPNs), a family of blood cancers. Essential thrombocythaemia, a form of MPN, is currently treated with hydroxycarbamide and interferon, which act without targeting the disease-driving cells.
Timeline
October 2025: Alethio emerged from stealth.
November 5, 2026: Alethio announced the $90 million series A close.
First half of 2028: Dosing in the essential thrombocythaemia studies is expected to begin.
The Tech Race
Alethio's targeted approach contrasts with the non-targeted hydroxycarbamide and interferon standard of care for essential thrombocythaemia. The company's pitch is that ATX-011 could extend benefits across MPNs regardless of driver mutation, though this remains a projection.
Patients with essential thrombocythaemia will not have access to ATX-011 until clinical trials advance, with dosing not expected until the first half of 2028. Until then, hydroxycarbamide and interferon remain the available options.
The takeaway
The trajectory to watch is whether a mutation-agnostic, selectively acting antibody can outperform non-targeted standards in essential thrombocythaemia. The first verifiable checkpoint is dosing in the ET studies, expected in the first half of 2028.
What happens next
Dosing in the essential thrombocythaemia studies is expected to commence in the first half of 2028, the next verifiable milestone for ATX-011.
Further reading
Track the broader field in Biotech, where targeted therapy development is moving quickly.
